Calliditas Therapeutics, a Swedish biotech developing therapies for orphan kidney and liver diseases, raised $90 million in an upsized IPO by offering 4.6 million ADS equivalents at $19.50 per ADS. It originally planned to raise $75 million by offering 3.8 million ADS equivalents. Its last close on the Nasdaq Stockholm (CALTX) was SEK 93.90 per common share, or $20.40 per ADS ($1 = SEK 9.2047). Calliditas now commands a fully diluted market value of $467 million.
Calliditas Therapeutics plans to list on the Nasdaq under the symbol CALT. Citi, Jefferies and Stifel acted as lead managers on the deal.
Calliditas Therapeutics prices upsized US IPO at $19.50 per ADS, at slight discount to Stockholm listing
June 5, 2020

